AEMD is going through a reverse split in preparation for uplisting to NASDAQ. Very high potential biotech company. The CEO stated earlier this year that uplisting in 2015 was a goal and the process just got started.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.